SEC Form 4 · accession 0001209191-17-062216
INNOVATE BIOPHARMACEUTICALS, INC. · INNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Lewis Olert
Officer — CFO
Period of report
Nov 9, 2017
Accepted (ET)
Nov 21, 2017 · 7:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551986
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 9, 2017 | A | 10,000 | $0.00 | A | 60,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares of restricted common stock granted under Issuer's 2012 Omnibus Incentive Plan.
- F2Such shares vest one-half on the one year anniversary of the grant date and one-half on the two year anniversary of the grant date. Vesting may accelerate upon a change of control.